IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
Journal
Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
02
10
2020
accepted:
12
01
2021
pubmed:
7
2
2021
medline:
30
3
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19). In this study, COVID-19 ARDS patients admitted to the Azienda Socio Sanitaria Territoriale of Lecco, Italy, between March 5th to April 15th, 2020, and who had received anakinra off-label were retrospectively evaluated and compared with a cohort of matched controls who did not receive immunomodulatory treatment. The primary end point was survival at day 28. The population consisted of 112 patients (56 treated with anakinra and 56 controls). Survival at day 28 was obtained in 69 patients (61.6%) and was significantly higher in anakinra-treated patients than in the controls (75.0 versus 48.2%,
Identifiants
pubmed: 33547169
pii: jimmunol.2001126
doi: 10.4049/jimmunol.2001126
pmc: PMC7980530
doi:
Substances chimiques
IL1RN protein, human
0
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1569-1575Informations de copyright
Copyright © 2021 by The American Association of Immunologists, Inc.
Références
Genes Dis. 2020 Dec;7(4):520-527
pubmed: 32837983
Arch Med Res. 2020 Oct;51(7):608-612
pubmed: 32682575
Clin Exp Rheumatol. 2016 May-Jun;34(3):531-8
pubmed: 26940286
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Rheum Dis. 2020 Oct;79(10):1381-1382
pubmed: 32376597
Autoimmun Rev. 2020 Jul;19(7):102573
pubmed: 32387470
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1
pubmed: 32411313
Lancet Respir Med. 2020 Apr;8(4):e18
pubmed: 32145829
Lancet Rheumatol. 2020 Jun;2(6):e358-e367
pubmed: 32373790
Arthritis Rheumatol. 2020 Dec;72(12):1990-1997
pubmed: 32602262
Rheumatology (Oxford). 2020 Aug 1;59(8):2171-2173
pubmed: 32568376
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Infez Med. 2020 Ahead of print Jun 1;28(2):143-152
pubmed: 32275256
Int J Infect Dis. 2020 Aug;97:215-218
pubmed: 32422376
Br J Haematol. 2020 Jul;190(2):e80-e83
pubmed: 32438450
BMJ Evid Based Med. 2020 Sep 15;:
pubmed: 32934000
J Autoimmun. 2020 Dec;115:102537
pubmed: 32843231
ACR Open Rheumatol. 2020 May;2(5):276-282
pubmed: 32267081
Lancet Rheumatol. 2020 Jul;2(7):e393-e400
pubmed: 32835245
World J Clin Cases. 2020 Oct 6;8(19):4280-4285
pubmed: 33083387
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Int J Infect Dis. 2020 Jul;96:607-609
pubmed: 32437934
Rheumatology (Oxford). 2011 Mar;50(3):552-62
pubmed: 21078627
J Allergy Clin Immunol. 2020 Jul;146(1):213-215
pubmed: 32437739
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Clin Microbiol Infect. 2021 Feb;27(2):215-227
pubmed: 33161150